PowderMRP Under Process
Official PMBI MRP is being updated for catalog code 2663.
Locate Jan Aushadhi KendraClinical Overview
Formoterol Fumarate (6mcg/12mcg) and Budesonide (100mcg/200mcg/400mcg Inhaler, Rotacaps, Powder, or Nebuliser Suspension) is a gold-standard fixed-dose combination on the WHO Model List of Essential Medicines. Budesonide is a potent inhaled glucocorticoid that suppresses airway mucosal inflammation, reduces microvascular permeability, and decreases hyperresponsiveness. Formoterol is a rapid-onset, long-acting beta-2 adrenergic agonist (LABA) that stimulates adenylyl cyclase, relaxes bronchial smooth muscle within 1-3 minutes, and provides sustained bronchodilation for >12 hours. Recommended by GINA guidelines as preferred Maintenance and Reliever Therapy (SMART / MART). Indicated for maintenance and rescue relief of bronchial asthma and symptomatic maintenance of Chronic Obstructive Pulmonary Disease (COPD).
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Inhaler (MDI): Shake canister well. Exhale completely, place mouthpiece between teeth and lips, press canister while taking a slow, deep breath, and hold breath for 10 seconds. Use a spacer device for optimal lung deposition. Rotacaps/DPI: Insert capsule into dry powder inhaler device, pierce, and inhale forcefully and deeply. CRITICAL: Rinse mouth thoroughly with water and spit out after each use to prevent oral candidiasis (thrush) and dysphonia.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Oral candidiasis (oral thrush), hoarseness (dysphonia), throat irritation, tremor, palpitations, headache. Rare/Severe: Paradoxical bronchospasm, hypokalemia, cardiac arrhythmias, and increased pneumonia risk in severe COPD.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Always rinse mouth with water and spit out after inhalation. Do NOT swallow rotacaps; they are for inhalation only via the specific inhaler device. Never discontinue abruptly. Seek emergency care if symptoms rapidly worsen and do not respond to bronchodilators.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, pulmonological diagnosis, or respiratory management recommendations. Inhalation therapies and allergy medications should be used strictly under the guidance of a qualified pulmonologist or registered medical practitioner.
Budesonide Nebuliser Suspension 1mg per 2ml
Budesonide Inhalation / Nebuliser Suspension (100mcg, 200mcg MDI; 400mcg Rotacaps; 1mg/2ml Respules) is a potent inhaled glucocorticoid on the WHO Model List of Essential Medicines. It diffuses into airway epithelial cells, binding to cytoplasmic glucocorticoid receptors to inhibit multiple pro-inflammatory transcription factors (NF-kB, AP-1), dramatically reducing recruitment of eosinophils, T-lymphocytes, and mast cells while downregulating inflammatory cytokines. Undergoes reversible intracellular esterification with fatty acids, creating a prolonged mucosal depot. Indicated for maintenance treatment of bronchial asthma, croup (laryngotracheobronchitis in infants/children), and severe COPD.
Budesonide Inhalation 100mcg
Budesonide Inhalation / Nebuliser Suspension (100mcg, 200mcg MDI; 400mcg Rotacaps; 1mg/2ml Respules) is a potent inhaled glucocorticoid on the WHO Model List of Essential Medicines. It diffuses into airway epithelial cells, binding to cytoplasmic glucocorticoid receptors to inhibit multiple pro-inflammatory transcription factors (NF-kB, AP-1), dramatically reducing recruitment of eosinophils, T-lymphocytes, and mast cells while downregulating inflammatory cytokines. Undergoes reversible intracellular esterification with fatty acids, creating a prolonged mucosal depot. Indicated for maintenance treatment of bronchial asthma, croup (laryngotracheobronchitis in infants/children), and severe COPD.
Budesonide Inhalation 200mcg
Budesonide Inhalation / Nebuliser Suspension (100mcg, 200mcg MDI; 400mcg Rotacaps; 1mg/2ml Respules) is a potent inhaled glucocorticoid on the WHO Model List of Essential Medicines. It diffuses into airway epithelial cells, binding to cytoplasmic glucocorticoid receptors to inhibit multiple pro-inflammatory transcription factors (NF-kB, AP-1), dramatically reducing recruitment of eosinophils, T-lymphocytes, and mast cells while downregulating inflammatory cytokines. Undergoes reversible intracellular esterification with fatty acids, creating a prolonged mucosal depot. Indicated for maintenance treatment of bronchial asthma, croup (laryngotracheobronchitis in infants/children), and severe COPD.
Formoterol 6mcg + Budesonide 200mcg Rotacaps
Formoterol Fumarate (6mcg/12mcg) and Budesonide (100mcg/200mcg/400mcg Inhaler, Rotacaps, Powder, or Nebuliser Suspension) is a gold-standard fixed-dose combination on the WHO Model List of Essential Medicines. Budesonide is a potent inhaled glucocorticoid that suppresses airway mucosal inflammation, reduces microvascular permeability, and decreases hyperresponsiveness. Formoterol is a rapid-onset, long-acting beta-2 adrenergic agonist (LABA) that stimulates adenylyl cyclase, relaxes bronchial smooth muscle within 1-3 minutes, and provides sustained bronchodilation for >12 hours. Recommended by GINA guidelines as preferred Maintenance and Reliever Therapy (SMART / MART). Indicated for maintenance and rescue relief of bronchial asthma and symptomatic maintenance of Chronic Obstructive Pulmonary Disease (COPD).